RxDoctor Payments Data

Julie Waight

Family · Brookfield, CTNPI 1871594788

Payments from drug & device makers

$4,939in general payments, 2019–2025

Across 370 payments — averaging $13.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$699
  • Teva Pharmaceuticals USA, Inc.$518
  • Pfizer$392
  • Impel Pharmaceuticals Inc.$340
  • Biohaven Pharmaceutical Holding Company Ltd.$317
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$4,920100%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,939 in reported general payments places this provider in the 90th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$6,940
Medicare patients
26
Services billed
60

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate56$78,873
Emgality PenGalcanezumab-Gnlm42$38,115
BotoxOnabotulinumtoxina22$25,539
Aimovig AutoinjectorErenumab-Aooe22$20,085
QuliptaAtogepant15$19,548
UbrelvyUbrogepant13$12,844
Sumatriptan Succinate48$2,529
Oxycodone Hcl47$963
Ketorolac Tromethamine20$596
Morphine Sulfate ErMorphine Sulfate47$591
Lidocaine11$571
Nadolol13$545
Topiramate28$534
Cyclobenzaprine Hcl39$431
Tizanidine Hcl30$383

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$392$78,87356 claims
AbbVieBotox, Qulipta, Ubrelvy$1,471$57,93150 claims
Upsher-smith Laboratories LLCTopiramate$77$53428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,596 family providers in Connecticut.

Other family in Brookfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →